Abstracts tagged "animal models and lupus nephritis"

Abstract Number: 1837 • 2017 ACR/ARHP Annual Meeting
Development of Murine SLE in the Absence of BAFF
William Stohl¹, Ning Yu¹, Samantha Chalmers², Chaim Putterman³ and Chaim O. Jacob¹, ¹Division of Rheumatology, Keck School of Medicine of University of Southern California, Los Angeles, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: BAFF is a vital survival and differentiation factor for B cells. In human SLE, clinical efficacy with any of 4 different BAFF antagonists is…
Abstract Number: 2561 • 2017 ACR/ARHP Annual Meeting
BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Samantha Chalmers¹, Elizabeth Glynn², Mark Panzenbeck², Josephine Pelletier², Todd Bosanac², Sara Khalil², Evan Der³, Leal Herlitz⁴, Deborah Webb², Gerald Nabozny⁵, Jay S. Fine², Elliott Klein², Donald Souza⁶, Chaim Putterman⁷ and Meera Ramanujam², ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Cleveland Clinic, Cleveland, OH, ⁵[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁶Immunology & Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Bruton's tyrosine kinase (BTK) plays an important role in B cell and FcR mediated myeloid cell activation. We recently described a selective BTK inhibitor,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].